Latest Period
Q4 2025
Security Snapshot
Candel Therapeutics, Inc. - Common Stock (CADL) Institutional Ownership
CUSIP: 137404109
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
84
Shares (Excl. Options)
23,634,025
Price
$5.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- CADL on Nasdaq
- Shares outstanding
- 73,330,024
- Price per share
- $4.95
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 23,634,025
- Total reported value
- $133,509,415
- % of total 13F portfolios
- 0%
- Share change
- +963,513
- Value change
- +$5,752,184
- Number of holders
- 84
- Price from insider filings
- $4.95
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CADL - Candel Therapeutics, Inc. - Common Stock is tracked under CUSIP 137404109.
- 84 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 84 to 17 between Q4 2025 and Q1 2026.
- Reported value moved from $133,509,415 to $7,754,434.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 84 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 137404109?
CUSIP 137404109 identifies CADL - Candel Therapeutics, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 137404109:
Significant Owners of Candel Therapeutics, Inc. - Common Stock (CADL) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +63% | $30,582,610 | +$11,592,390 | 6,318,721 | +61% | FMR LLC | 31 Jan 2025 |
| Manning Paul B | 7.9% | $29,997,375 | 5,790,999 | Paul B Manning | 16 Dec 2024 | |||
| BlackRock, Inc. | 4.2% | -20% | $15,091,319 | +$1,079,230 | 3,079,861 | +7.7% | BlackRock, Inc. | 31 Mar 2026 |
| ACORN BIOVENTURES, L.P. | 5.2% | $14,115,428 | 2,580,517 | Anders Hove | 25 Jun 2025 | |||
| BAKER BROS. ADVISORS LP | 5% | -26% | $11,882,723 | -$2,550,075 | 2,455,108 | -18% | Baker Bros. Advisors LP | 31 Mar 2025 |
As of 31 Dec 2025, 84 institutional investors reported holding 23,634,025 shares of Candel Therapeutics, Inc. - Common Stock (CADL). This represents 32% of the company’s total 73,330,024 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Candel Therapeutics, Inc. - Common Stock (CADL) together control 31% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 11% | 8,234,299 | +0.01% | 0% | $46,523,790 |
| BlackRock, Inc. | 3.9% | 2,861,689 | +20% | 0% | $16,168,544 |
| ACORN CAPITAL ADVISORS, LLC | 3.5% | 2,580,517 | 0% | 4.9% | $14,579,921 |
| VANGUARD GROUP INC | 3.1% | 2,305,060 | +15% | 0% | $13,023,588 |
| Portolan Capital Management, LLC | 2.3% | 1,695,367 | +22% | 0.51% | $9,578,824 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 977,512 | +5.3% | 0% | $5,523,837 |
| STATE STREET CORP | 1.1% | 792,218 | +15% | 0% | $4,476,032 |
| Halter Ferguson Financial Inc. | 1% | 748,055 | +7.2% | 0.93% | $4,226,509 |
| Sands Capital Alternatives, LLC | 0.55% | 405,837 | 0% | 0.44% | $2,292,979 |
| NORTHERN TRUST CORP | 0.4% | 295,438 | -3.7% | 0% | $1,669,225 |
| CITADEL ADVISORS LLC | 0.31% | 226,356 | -10% | 0% | $1,278,911 |
| Tanager Wealth Management LLP | 0.27% | 198,175 | 0% | 0.11% | $1,119,689 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.19% | 137,408 | -39% | 0% | $776,355 |
| MORGAN STANLEY | 0.18% | 134,031 | +76% | 0% | $757,275 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.17% | 121,004 | 0% | 0% | $683,673 |
| UBS Group AG | 0.14% | 104,339 | +11% | 0% | $589,515 |
| TWO SIGMA INVESTMENTS, LP | 0.14% | 99,200 | -27% | 0% | $560,480 |
| Bank of New York Mellon Corp | 0.13% | 95,208 | +0.68% | 0% | $537,924 |
| Nuveen, LLC | 0.13% | 92,482 | -56% | 0% | $522,523 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.11% | 82,346 | +0.15% | 0% | $465,250 |
| Focus Partners Wealth | 0.11% | 81,816 | 0% | $462,261 | |
| WELLS FARGO & COMPANY/MN | 0.1% | 73,899 | +181% | 0% | $417,530 |
| BARCLAYS PLC | 0.09% | 69,344 | +16% | 0% | $391,793 |
| ALLIANCEBERNSTEIN L.P. | 0.09% | 69,110 | 0% | 0% | $390,472 |
| Torrey Growth & Income Advisors | 0.09% | 66,750 | 0.13% | $377,138 |
Institutional Holders of Candel Therapeutics, Inc. - Common Stock (CADL) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,583,335 | $7,754,434 | +$1,056,006 | $4.90 | 17 |
| 2025 Q4 | 23,634,025 | $133,509,415 | +$5,752,184 | $5.65 | 84 |
| 2025 Q3 | 22,668,478 | $115,621,483 | -$1,871,335 | $5.10 | 81 |
| 2025 Q2 | 23,037,394 | $116,569,933 | +$8,831,720 | $5.06 | 78 |
| 2025 Q1 | 21,190,126 | $119,726,836 | +$12,537,033 | $5.65 | 82 |
| 2024 Q4 | 17,950,985 | $155,743,026 | +$97,379,454 | $8.68 | 70 |
| 2024 Q3 | 6,693,196 | $46,384,699 | +$3,074,083 | $6.93 | 51 |
| 2024 Q2 | 5,961,761 | $36,964,279 | +$13,959,987 | $6.20 | 45 |
| 2024 Q1 | 3,780,257 | $5,972,529 | -$231,572 | $1.58 | 18 |
| 2023 Q4 | 4,027,160 | $5,919,504 | -$1,196,574 | $1.47 | 21 |
| 2023 Q3 | 5,257,852 | $4,856,205 | -$147,500 | $0.92 | 19 |
| 2023 Q2 | 5,370,044 | $6,766,125 | -$142,743 | $1.26 | 19 |
| 2023 Q1 | 5,478,268 | $7,437,200 | +$69,459 | $1.35 | 20 |
| 2022 Q4 | 5,420,630 | $9,702,154 | -$1,788,500 | $1.79 | 20 |
| 2022 Q3 | 6,080,809 | $19,096,287 | -$834,398 | $3.14 | 22 |
| 2022 Q2 | 6,345,954 | $20,561,000 | -$1,159,878 | $3.24 | 21 |
| 2022 Q1 | 6,674,026 | $33,969,000 | -$1,719,786 | $5.08 | 21 |
| 2021 Q4 | 6,951,728 | $54,359,000 | +$875,765 | $7.82 | 20 |
| 2021 Q3 | 4,884,284 | $52,945,000 | +$44,146,000 | $10.84 | 12 |